Amneal Pharmaceuticals Simplifies Corporate Structure
11.17.23
This is only gets display when printing
Simpson Thacher represented Amneal Pharmaceuticals, Inc. (“Amneal”) in connection with a series of transactions involving Amneal and certain of its subsidiaries which resulted in the elimination of Amneal’s umbrella partnership – C corporation (“Up-C”) structure and simplified its equity capital structure to a single class of common stock.
Amneal (NYSE: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business, as well as deepening portfolios in institutional injectables, biosimilars and select international markets.
The Simpson Thacher team included Richard Fenyes, Anna Jarman and Emily Anne Owen (Capital Markets); Karen Kelley, Jennifer Nadborny and Bettina Elstroth (Public Company Advisory Practice); Andrew Purcell and Tova Pfeffer (Tax); Jakob Rendtorff (M&A); and Jamin Koslowe (Executive Compensation and Employee Benefits).